Navigation Links
Drugs & Bugs: A New App from Monthly Prescribing Reference
Date:2/23/2012

NEW YORK, Feb. 23, 2012 /PRNewswire/ -- Monthly Prescribing Reference (MPR) is pleased to announce the launch of the Drugs & Bugs App, an essential resource for healthcare professionals. The app provides comprehensive information on antibiotic spectrum of efficacy against microorganisms. Clinicians may use the searchable alpha indices or search drugs and bugs by bacterial class or pharmacological class to begin their query.

The Drugs & Bugs App features:

  • A database of more than 100 antibiotics and nearly 200 bacterial pathogens
  • Smart Search capability by pathogen, type of infection, brand and generic drug names
  • Quick-to-read results on spectrum of activity
  • Comprehensive drug monographs for anti-infective agents
  • Useful comparative charts by drug class
  • Clinical calculators

Drugs & Bugs was developed by MPR and US Biomedical Information Systems (USBMIS), MPR's app development partner, in cooperation with Philip Chung, PharmD, BCPS; Clinical Pharmacy Manager in Infectious Diseases at Montefiore Medical Center, NY. The drug monographs are frequently updated and reviewed by MPR's team of pharmacists and physicians.

"Choosing an empiric antibiotic regimen can be daunting," said Dr. Chung. "The Drugs & Bugs App is a useful tool for selecting empiric antibiotic regimens before susceptibility results become available. The app also aids clinicians in the selection of antibiotic regimens with the narrowest spectrum possible based on susceptibility results." 

Drugs & Bugs is now available for Apple iOS (iPhone, iPad, iPod Touch) and Android (Android phones and tablets, Kindle Fire, NOOK) platforms and can be downloaded at empr.com/drugsandbugs, the iTunes App Store, Android Market, Amazon Appstore, and NOOK Apps.

"The innovative use of our drug information content to create new and useful products for clinicians is integral to our digital strategy," said Tammy Chernin, VP, MPR Drug Information & Product Development. "The need to limit the development of resistance with the judicious use of antibiotics is of paramount importance. The Drugs & Bugs App is a fantastic example of MPR's commitment to providing clinicians with tools that support their prescribing decisions."

Dr. Darwin Ang, MD, PhD, MPH agreed.  Dr. Ang, founder of USBMIS, said, "MPR already provides a great product, and they are strongly committed to using the latest technology, as in the Drugs & Bugs App, to disseminate their crucial data."

For more than 26 years, healthcare professionals in the United States have relied on the print editions of MPR to deliver up-to-date, concise drug information at the point-of-care. That same drug information is also available online, as well as on mobile devices and smartphones, and has been enhanced with digital clinical tools and resources. The pharmacist-editors at MPR are dedicated to bringing the highest quality drug information to all clinicians, with the most powerful and flexible clinical decision support tools available.

About MPR and Haymarket Media Inc.

Monthly Prescribing Reference is published by Haymarket Media Inc. (HMI), a global publication and communications company with operations on five continents. Founded in 1957 and headquartered in the United Kingdom, HMI publishes titles in 23 languages in more than 100 nations. In the United States HMI publishes a number of healthcare journals, including MPR (primary care and specialty editions), The Clinical Advisor, and Renal & Urology News. Since 1985, MPR has been the most widely used drug reference by healthcare professionals in a wide variety of specialties and practice settings. 


'/>"/>
SOURCE Monthly Prescribing Reference
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
4. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
8. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):